About: Pulmonary Fibrosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pulmonary Fibrosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pulmonary Fibrosis
Creator	Brenner, D Strieter, Robert Belperio, John Keane, Michael Zisman, David Lynch, Joseph Phan, S Varga, J
Source	PMC
abstract	Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing lung disease limited to the lungs and associated with the histologic appearance of usual interstitial pneumonia (UIP) on surgical lung biopsy. The estimated prevalence in the United States is between 35,000 and 55,000 cases, and evidence suggests that the prevalence is increasing for IPF. Risk factors associated with pulmonary fibrosis include smoking, environmental exposures, gastroesophageal reflux disease, commonly prescribed drugs, diabetes mellitus, infectious agents, and genetic factors. The diagnosis requires a careful history and physical examination, characteristic physiological and radiological studies, and, in some cases, a surgical lung biopsy. The natural history of IPF is not known, but evidence supports the concept of a continuum of idiopathic interstitial pneumonias that may overlap in time. Most patients with IPF succumb to respiratory failure, cardiovascular disease, lung cancer, pulmonary embolism, infection, and other health problems. The median survival time for patients with IPF is less than 3 yr. Factors that predict poor outcome include older age, male gender, severe dyspnea, history of cigarette smoking, severe loss of lung function, appearance and severity of fibrosis on radiological studies, lack of response to therapy, and prominent fibroblastic foci on histopathologic evaluation. Conventional therapy (corticosteroids, azathioprine, cyclophosphamide) provides only marginal benefit. Lung transplantation should be considered for patients with IPF refractory to medical therapy. In light of the poor prognosis and lack of response to available anti-inflammatory therapy, alternative approaches to therapy are being pursued. Emerging strategies to treat patients with IPF include agents that inhibit epithelial injury or enhance repair, anticytokine approaches, agents that inhibit fibroblast proliferation or induce fibroblast apoptosis, and other novel approaches.
has issue date	2005-01-01(xsd:dateTime)
bibo:doi	10.1385/1-59259-940-0:003
bibo:pmid	16130230
has license	no-cc
sha1sum (hex)	f537cd519de072bfe92ef0d4df5956ad90862884
schema:url	https://doi.org/10.1385/1-59259-940-0:003
resource representing a document's title	Pulmonary Fibrosis
has PubMed Central identifier	PMC7120641
has PubMed identifier	16130230
schema:publication	Fibrosis Research
resource representing a document's body	covid:f537cd519de072bfe92ef0d4df5956ad90862884#body_text
is schema:about of	named entity 'bleomycin' named entity 'lung tissue' named entity 'lipids' named entity 'PFTs' named entity 'radiographic' named entity 'Pleural effusions' named entity 'hypersensitivity' named entity 'Clinical data' named entity 'platelet-derived growth factor' named entity 'DAD' named entity 'TGF-β' named entity 'interstitial pneumonia' named entity 'lesion' named entity 'IFN' named entity 'idiopathic' named entity 'risk factor' named entity 'nuclear medicine' named entity 'antidepressants' named entity 'crackles' named entity 'FEV' named entity 'radiographic' named entity 'IPF' named entity 'cellular functions' named entity 'rales' named entity 'UIP' named entity 'collagen' named entity 'IFN' named entity 'lung transplant' named entity 'steroid' named entity 'odds ratio' named entity 'lung function' named entity 'IPF' named entity 'endothelin' named entity 'triglycerides' named entity 'TGF-β' named entity 'idiopathic' named entity 'intramuscularly' named entity 'surgical specimen' named entity 'prednisolone' named entity 'fibrosis' named entity 'gas exchange' named entity 'collagen' named entity 'CT scans' named entity 'IPF' named entity 'inflammation' named entity 'upper lobe' named entity 'lung disorders' named entity 'BALF' named entity 'IPF' named entity 'fibrosis' named entity 'UIP' named entity 'apoptosis' named entity 'gout' named entity 'collagen' named entity 'prednisolone' named entity 'lung volume' named entity 'interstitial lung disease' named entity 'UIP' named entity 'TGF-β' named entity 'biopsy' named entity 'CFA' named entity 'UIP' named entity 'malignancies' named entity 'alveolar epithelium' named entity 'fibrosis' named entity 'subcutaneous' named entity 'mortality rates' named entity 'prognosis' named entity 'hypertensive heart disease' named entity 'histopathological' named entity 'pulmonary fibrosis' named entity 'idiopathic pulmonary fibrosis' named entity 'natural history' named entity '2.0'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software